Cheetah Medical received 510(k) marketing clearance by the US Food and Drug Administration (FDA) for the NIBP functionality, provided by SunTech Medical, in its NICOM Reliant Hemodynamic Monitoring System. The NIBP Option for the NICOM System platform and other feature enhancements add new parameters to provide a comprehensive suite of information for functional cardiac and systemic vascular monitoring –all without the need for invasive cardiovascular monitoring methods that are associated with increased potential costs and patient risks. The new parameters include Noninvasive Blood Pressure (NIBP), Total Peripheral Resistance (TPR), Stroke Volume Variation (SVV), Cardiac Power (CP), and Change in Thoracic Fluid Content (TFCd). “Noninvasive hemodynamic monitoring using the NICOM System is quickly gaining interest as a new standard of monitored care, particularly in hospitals, where the average patient is older, sicker and where accurate clinical decision-making often hinges on knowing the patient’s real-time hemodynamic status,” said Yoav Avidor, MD, CEO of Cheetah Medical. “US market availability of the NICOM System with integrated Suntech Medical NIBP capabilities furthers our commitment to offer clinicians a complete, continuous noninvasive profile of the patient’s hemodynamic status, while reducing the costs and risks formerly associated with obtaining it,” added Dr. Avidor.